Architecting autonomy: A design pattern for high-compute, governed agents in biotech

In production systems today, most AI agents operate as lightweight dispatchers. They parse a prompt, make an API call, retrieve a record, and hand back control. Their execution is fast, stateless and cheap. Biotechnology does not work this way. Folding a protein target, screening a 50,000 compound ligand library, or evaluating structure-activity relationships (SAR) are not quick API lookups. They are sustained, stateful, GPU-bound simulations that run for minutes or even hours across specialized silicon. When you ask a general-purpose large language model (LLM) endpoint to coordinate a complex